Evaxion A/S EVAX
At closeNov 3, 2026, 4:00 PM EST
After hours · Nov 3, 4:00 PM ET
- YTD
- -37.95%
- 1 year
- -48.70%
- Market cap
- 26.70M
- Revenue (ttm)
- 3.29M
- EPS (ttm)
- -1.00
- Shares out
- 5.87M
- Forward P/E
- -0.72
- YTD return
- -37.95%
- 1-year return
- -48.70%
- Volume
- 28.87K
- Avg volume
- 234.82K
- Open
- 3.19
- Previous close
- 2.92
- Day's range
- 2.93 – 3.19
- 52-week range
- 2.72 – 6.92
- Beta
- -0.23
- Price target
- 11.56 (+290.6%)
- Earnings date
- Aug 14, 2024
2Y -10.22 (-77.42%)
Key statistics
- Enterprise value
- 46.26M
- PEG ratio
- 0.00
- Price / sales
- 1.62
- Price / book
- 69.82
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 4.58M
- Total debt
- 0
- Return on equity
- 0.00%
- Short % of float
- 0.74%
- 50-day average
- 1.95
- 200-day average
- 2.95
Analyst view
- Target (low)
- 7.00
- Target (mean)
- 11.56
- Target (high)
- 18.00
- Strong buy1
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 14, 2024
Expected Aug 14, 2024. Consensus EPS estimate -0.03.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Oct 31, 2024 | Sep 1, 2024 | -0.12 | -0.04 | +0.08 | +66.67% |
| Aug 14, 2024 | Jun 1, 2024 | 0.02 | — | — | — |
| Aug 14, 2024 | Jun 1, 2024 | 0.02 | -0.12 | -0.14 | -700.00% |
| May 28, 2024 | Mar 1, 2024 | 0.00 | — | — | — |
| May 28, 2024 | Mar 1, 2024 | 0.00 | 0.03 | — | — |
| Mar 27, 2024 | Dec 1, 2023 | 0.00 | -0.16 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 1, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 26, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 20, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 16, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 1, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 4, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About Evaxion A/S
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Denmark
- Website
- evaxion-biotech.com
News
Evaxion to present broad biomarker data from phase 2 trial with personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting 
Evaxion receives International Prix Galien Award for AI-Immunology™ as best digital health solution 
Evaxion A/S (EVAX) Discusses EVX-01 Phase II Clinical and Immune Data in Advanced Melanoma Transcript 
Evaxion A/S (NASDAQ:EVAX) Shares Break Below 200 Day Moving Average – What’s Next? 
12 Health Care Stocks Moving In Friday's Pre-Market Session 
Evaxion Reports All Patients Maintained Clinical Response With No Tumor Progression Through Year Three Of EVX-01 Monotherapy In Advanced Melanoma Phase 2 Trial, 89% Of Vaccine Neoantigens Triggered T-Cell Responses 
Evaxion announces 89% vaccine target precision and sustained T-cell and clinical responses at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01 
Evaxion reports sustained clinical responses for all patients at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01 
12 Health Care Stocks Moving In Friday's Pre-Market Session 
12 Health Care Stocks Moving In Monday's Pre-Market Session
Your note
Sign in to keep a note on EVAX — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Armistice Capital, LLC | 8.23% | 483,000 | 438.42K | Sep 29, 2024 |
| Invst, LLC | 0.74% | 43,200 | 39.21K | Sep 29, 2024 |
| Citadel Advisors Llc | 0.25% | 14,825 | 13.46K | Sep 29, 2024 |
| Beacon Capital Management, LLC | 0.08% | 4,863 | 4.41K | Sep 29, 2024 |
| Blackrock Inc. | 0.03% | 1,512 | 1.37K | Sep 29, 2024 |
| JP Morgan Chase & Company | 0.01% | 780 | 708 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.06% | 3,348 | 3.04K | Oct 30, 2024 |